secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-004838
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones
--------------------------------------------------------------------------------

- Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.
- Licensed SP16 IV (royalty-free, global) for cancer neuropathy; Phase 1b fully funded by NCI development grant.
- Developed chemically equivalent synthetic Halneuron for Phase 3; new IP if granted extends protection to 2046.
- Milestones: final Phase 2b data Q3 2026, SP16 IND filing Q1 2026, dosing Phase 1b by mid-2026.
- Completed January financing (undisclosed amount) to fund pipeline; end-of-Phase 2 FDA submission targeted late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/0001104659-26-004838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465926004838/dwtx-20260120x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-004838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer